BeOne Medicines (ONC) Competitors $313.67 -0.30 (-0.10%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ONC vs. SNY, GSK, TAK, ARGX, INSM, BNTX, TEVA, SMMT, GMAB, and VTRSShould you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. BeOne Medicines vs. Its Competitors Sanofi GSK Takeda Pharmaceutical argenex Insmed BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Sanofi (NASDAQ:SNY) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends. Do institutionals & insiders hold more shares of SNY or ONC? 14.0% of Sanofi shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend SNY or ONC? Sanofi presently has a consensus price target of $62.00, suggesting a potential upside of 20.74%. BeOne Medicines has a consensus price target of $330.89, suggesting a potential upside of 5.49%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.11BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, SNY or ONC? Sanofi has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Which has preferable valuation and earnings, SNY or ONC? Sanofi has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$44.46B2.84$6.02B$4.1612.34BeOne Medicines$3.81B9.02-$644.79M-$1.73-181.31 Is SNY or ONC more profitable? Sanofi has a net margin of 21.47% compared to BeOne Medicines' net margin of -3.89%. Sanofi's return on equity of 16.86% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Sanofi21.47% 16.86% 9.63% BeOne Medicines -3.89%-1.22%-0.72% Does the media favor SNY or ONC? In the previous week, Sanofi had 12 more articles in the media than BeOne Medicines. MarketBeat recorded 20 mentions for Sanofi and 8 mentions for BeOne Medicines. Sanofi's average media sentiment score of 1.42 beat BeOne Medicines' score of 1.23 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 17 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 4 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySanofi beats BeOne Medicines on 13 of the 17 factors compared between the two stocks. Get BeOne Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricBeOne MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.38B$2.54B$5.82B$9.77BDividend YieldN/A1.67%4.40%4.06%P/E Ratio-181.3122.9031.3026.05Price / Sales9.02510.41433.43108.36Price / CashN/A179.1038.0259.36Price / Book9.125.939.536.60Net Income-$644.79M$31.83M$3.26B$265.65M7 Day Performance-2.39%1.89%2.13%1.99%1 Month Performance5.81%1.62%3.21%0.45%1 Year PerformanceN/A9.25%30.18%18.87% BeOne Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCBeOne Medicines0.8669 of 5 stars$313.67-0.1%$330.89+5.5%N/A$34.38B$3.81B-181.3111,000SNYSanofi3.8206 of 5 stars$51.35+1.5%$62.00+20.7%-8.6%$126.09B$45.74B12.3482,878Positive NewsGSKGSK2.8659 of 5 stars$40.15+0.2%$37.38-6.9%-5.8%$81.67B$40.10B18.5968,629Trending NewsAnalyst RevisionTAKTakeda Pharmaceutical1.269 of 5 stars$15.50+1.3%N/A+2.8%$48.72B$30.09B51.6847,455News CoverageAnalyst DowngradeARGXargenex3.9981 of 5 stars$660.00-0.6%$746.81+13.2%+27.7%$40.62B$2.25B33.851,599Positive NewsINSMInsmed4.0085 of 5 stars$131.88-0.5%$132.57+0.5%+67.3%$28.03B$363.71M-23.101,271Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionBNTXBioNTech1.7574 of 5 stars$110.88+0.1%$135.80+22.5%+25.7%$26.63B$2.88B-69.306,772TEVATeva Pharmaceutical Industries3.4294 of 5 stars$18.47-1.8%$24.71+33.8%-0.5%$21.56B$16.54B-115.4136,830News CoveragePositive NewsSMMTSummit Therapeutics2.3863 of 5 stars$26.20+0.7%$32.85+25.4%+100.3%$19.32B$700K-25.94110Analyst ForecastGMABGenmab A/S3.8466 of 5 stars$24.65+0.9%$37.60+52.5%-9.8%$15.81B$3.26B12.392,682Positive NewsAnalyst DowngradeVTRSViatris1.6216 of 5 stars$10.65-0.4%$10.40-2.3%-9.4%$12.46B$14.12B-3.6732,000Analyst Upgrade Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives SMMT Alternatives GMAB Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONC) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access